These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28606656)

  • 1. Divergent antiarrhythmic effects of resveratrol and piceatannol in a whole-heart model of long QT syndrome.
    Ellermann C; Wolfes J; Kochhäuser S; Dechering DG; Reinke F; Wasmer K; Eckardt L; Frommeyer G
    Int J Cardiol; 2017 Sep; 243():233-238. PubMed ID: 28606656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ryanodine-receptor inhibition by dantrolene effectively suppresses ventricular arrhythmias in an ex vivo model of long-QT syndrome.
    Frommeyer G; Krawczyk J; Ellermann C; Bögeholz N; Kochhäuser S; Dechering DG; Fehr M; Eckardt L
    J Cardiovasc Electrophysiol; 2018 Mar; 29(3):471-476. PubMed ID: 29314443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
    Ellermann C; Sterneberg M; Kochhäuser S; Dechering DG; Fehr M; Eckardt L; Frommeyer G
    Europace; 2018 Oct; 20(10):1699-1706. PubMed ID: 29377987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome.
    Frommeyer G; Weller J; Ellermann C; Leitz P; Kochhäuser S; Lange PS; Dechering DG; Eckardt L
    Cardiovasc Toxicol; 2019 Apr; 19(2):129-135. PubMed ID: 30238354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic effect of vernakalant in an experimental model of Long-QT-syndrome.
    Frommeyer G; Clauss C; Ellermann C; Bogossian H; Dechering DG; Kochhäuser S; Reinke F; Pott C; Eckardt L
    Europace; 2017 May; 19(5):866-873. PubMed ID: 27702859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization.
    Milberg P; Frommeyer G; Kleideiter A; Fischer A; Osada N; Breithardt G; Fehr M; Eckardt L
    Heart Rhythm; 2011 Sep; 8(9):1492-500. PubMed ID: 21459164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the Na+/Ca2+ exchanger suppresses torsades de pointes in an intact heart model of long QT syndrome-2 and long QT syndrome-3.
    Milberg P; Pott C; Fink M; Frommeyer G; Matsuda T; Baba A; Osada N; Breithardt G; Noble D; Eckardt L
    Heart Rhythm; 2008 Oct; 5(10):1444-52. PubMed ID: 18929333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
    Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3.
    Milberg P; Reinsch N; Osada N; Wasmer K; Mönnig G; Stypmann J; Breithardt G; Haverkamp W; Eckardt L
    Basic Res Cardiol; 2005 Jul; 100(4):365-71. PubMed ID: 15944809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad antiarrhythmic effect of mexiletine in different arrhythmia models.
    Frommeyer G; Garthmann J; Ellermann C; Dechering DG; Kochhäuser S; Reinke F; Köbe J; Wasmer K; Eckardt L
    Europace; 2018 Aug; 20(8):1375-1381. PubMed ID: 29016765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization.
    Frommeyer G; Milberg P; Clauss C; Schmidt M; Ramtin S; Kaese S; Grundmann F; Grotthoff JS; Pott C; Eckardt L
    Europace; 2014 Aug; 16(8):1240-8. PubMed ID: 24696223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low proarrhythmic potential of citalopram and escitalopram in contrast to haloperidol in an experimental whole-heart model.
    Frommeyer G; Brücher B; von der Ahe H; Kaese S; Dechering DG; Kochhäuser S; Bogossian H; Milberg P; Eckardt L
    Eur J Pharmacol; 2016 Oct; 788():192-199. PubMed ID: 27328775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure.
    Milberg P; Pott C; Frommeyer G; Fink M; Ruhe M; Matsuda T; Baba A; Klocke R; Quang TH; Nikol S; Stypmann J; Osada N; Müller FU; Breithardt G; Noble D; Eckardt L
    Heart Rhythm; 2012 Apr; 9(4):570-8. PubMed ID: 22075452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
    Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
    J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.
    Frommeyer G; Ellermann C; Dechering DG; Kochhäuser S; Bögeholz N; Güner F; Leitz P; Pott C; Eckardt L
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1214-1219. PubMed ID: 27283775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits.
    Frommeyer G; Kaiser D; Uphaus T; Kaese S; Osada N; Rajamani S; Belardinelli L; Breithardt G; Eckardt L; Milberg P
    Heart Rhythm; 2012 Dec; 9(12):2051-8. PubMed ID: 23044390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model.
    Sossalla S; Wallisch N; Toischer K; Sohns C; Vollmann D; Seegers J; Lüthje L; Maier LS; Zabel M
    Cardiovasc Ther; 2014 Aug; 32(4):170-7. PubMed ID: 24785406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
    Milberg P; Ramtin S; Mönnig G; Osada N; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Pharmacol; 2004 Sep; 44(3):278-86. PubMed ID: 15475823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe proarrhythmic potential of risperidone compared to quetiapine in an experimental whole-heart model of proarrhythmia.
    Frommeyer G; von der Ahe H; Brücher B; Dechering DG; Lange PS; Reinke F; Wasmer K; Köbe J; Pott C; Mönnig G; Eckardt L
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1073-80. PubMed ID: 27405774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.